Celltrion’s active launching process for Truxima, starting to sell in Germany
Celltrion announced on the 18th that it has started to prepare for an official launch of ‘Truxima,’ the first antibody biosimilar for the treatment of blood cancer, even in Germany after the U.K. and Korea.
Truxima is an antibody biosimilar used to treat various types of blood cancer, like non-H...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
